Atazanavir-d9(Synonyms: BMS-232632-d9)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Atazanavir-d9 (Synonyms: BMS-232632-d9)

Atazanavir-d9 (BMS-232632-d9) 是 Atazanavir 的氘代物。Atazanavir (BMS-232632) 是一种高选择性的 HIV-1蛋白酶抑制剂，用于艾滋病毒感染的研究。Atazanavir 是 CYP3A4 的底物和抑制剂，也是 P-糖蛋白的抑制剂和诱导剂。Atazanavir 也是 SARS-CoV 3CLpro 的抑制剂，IC50 为 3.49 μM。

Atazanavir-d9(Synonyms: BMS-232632-d9)

Atazanavir-d9 Chemical Structure

CAS No. : 1092540-51-6

规格 是否有货
1 mg Check price and availability
5 mg Check price and availability
10 mg Check price and availability

* Please select Quantity before adding items.

生物活性

Atazanavir-d9 (BMS-232632-d9) is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

713.91

Formula

C38H43D9N6O7
CAS 号

1092540-51-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Wood R. Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96.

    [3]. Havlir DV, et al. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis. 2004 Jun 1;38(11):1599-604.

    [4]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务